Form C-U Tapville Franchising,

  
    C-U
    
      
        
          0001815192
          XXXXXXXX
        
        020-28552
      
      LIVE
      
        false
        false
        false
      
    
  
  
    
      At the close of the offering, the issuer closed on $423,511.12 and 70,369 number of securities.
      
        Tapville Franchising, Inc.
        
          Corporation
          DE
          06-08-2020
        
        
          216 S. WASHINGTON STREET
          PLEASE UPDATE THIS VALUE
          NAPERVILLE
          IL
          60540
        
        https://www.tapville.co
      
      N
      StartEngine Capital, LLC
      0001665160
      007-00007
    
    
      7 - 13 percent
      We charge 2% commission paid in equity or securities at the same rate as this offering.
      Other
      Class B Common Stock
      1600
      6.25000
      N/A
      10000.00
      Y
      Other
      At issuer's discretion, with priority given to StartEngine Owners
      3930000.00
      06-29-2022
    
    
      10.00
      1124958.00
      269425.00
      392921.00
      124054.00
      553754.00
      40697.00
      6831.00
      2213.00
      0.00
      0.00
      1018097.00
      99474.00
      477731.00
      50600.00
      0.00
      0.00
      -254151.00
      -288702.00
      AL
      AK
      AZ
      AR
      CA
      CO
      CT
      DE
      DC
      FL
      GA
      HI
      ID
      IL
      IN
      IA
      KS
      KY
      LA
      ME
      MD
      MA
      MI
      MN
      MS
      MO
      MT
      NE
      NV
      NH
      NJ
      NM
      NY
      NC
      ND
      OH
      OK
      OR
      PA
      PR
      RI
      SC
      SD
      TN
      TX
      UT
      VT
      VA
      WA
      WV
      WI
      WY
    
    
      
        Tapville Franchising, Inc.
        Joseph Tota
        President, CEO, Principal Executive Officer, Director, Principal Financial Officer and Principal Accounting Officer
      
      
        
          Jospeh Tota
          President, CEO, Principal Executive Officer, Director, Principal Financial Officer and Principal Accounting Officer
          07-01-2022
        
      
    
  

You May Also Be Interested In

• Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
• InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 25
• FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease